James D. Lewis, MD, MSCE; Brian L. Strom, MD, MPH
Acknowledgments: The authors thank Gerald Faich, MD, MPH, and Peter Honig, MD, for their thoughtful review of an earlier version of this editorial.
Requests for Single Reprints: James D. Lewis, MD, MSCE, Center for Epidemiology and Biostatistics, University of Pennsylvania, 7th Floor Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021; e-mail, email@example.com.
Disclaimer: Dr. Lewis has served as a consultant for several pharmaceutical companies, including Bayer, Centocor, Wyeth, and McNeil. He has also had research funded by Bayer, Centocor, and Whitehall-Robins. He has consulted for Bayer on issues related to phenylpropanolamine, a component of LipoKinetix. Otherwise, none of the consulting or research was related to dietary supplements. Dr. Strom is funded for his research and has served as a consultant to most of the major pharmaceutical manufacturers. He has worked with Wyeth on issues related to fen/phen. He has also consulted with Whitehall on issues related to phenylpropanolamine, a component of LipoKinetix. Otherwise, he has not been a consultant to any supplement manufacturer or researched supplements per se, although some pharmaceutical manufacturers market supplements as well.
Current Author Addresses: Drs. Lewis and Strom: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 7th Floor Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.
Ann Intern Med. 2002; 136:616-618.
Lewis JD, Strom BL. Balancing Safety of Dietary Supplements with the Free Market. Ann Intern Med. 2002;136:616-618. doi: 10.7326/0003-4819-136-8-200204160-00011
Download citation file:
Published: Ann Intern Med. 2002;136(8):616-618.
In this issue, Favreau and colleagues report on cases of hepatotoxicity in users of the dietary supplement LipoKinetix (1). This dietary supplement was marketed as a weight-loss product and contained norephedrine (also known as phenylpropanolamine), caffeine, yohimbine, diiodothyronine, and sodium usniate. The authors report the experience of seven patients, each taking LipoKinetix for weight loss, who experienced severe liver injury within 12 weeks of ingesting this product.
This and other recent reports of adverse outcomes associated with use of supplements [2, 3] highlight two important issues that merit further consideration: 1) regulation and safety of dietary supplements and 2) safety surveillance.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only